ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
126.134,94
-0,61%
S&P 500
6.040,53
-0,50%
US Dollar vs BRL
5,842
0,00%
Bitcoin
97.260,10
-3,39%
Brent Oil
76,385
0,00%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Altamira Therapeutics Ltd (CYTO)

  7. Altamira Therapeutics Ltd (CYTO) Notícias

CYTO

Altamira Therapeutics (CYTO)

Altamira Therapeutics Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CYTO
DataHoraFonteTítuloCódigoCompanhia
20/12/202410:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
20/12/202410:00GlobeNewswire Inc.Altamira Therapeutics Announces Transition from NASDAQ to OTC MarketsNASDAQ:CYTOAltamira Therapeutics Ltd
04/10/202417:01GlobeNewswire Inc.Altamira Therapeutics Provides Update on Nasdaq ListingNASDAQ:CYTOAltamira Therapeutics Ltd
27/09/202410:01GlobeNewswire Inc.Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal SprayNASDAQ:CYTOAltamira Therapeutics Ltd
24/09/202409:01GlobeNewswire Inc.Altamira Therapeutics Provides Business Update and First Half 2024 Financial ResultsNASDAQ:CYTOAltamira Therapeutics Ltd
20/09/202410:01GlobeNewswire Inc.Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024NASDAQ:CYTOAltamira Therapeutics Ltd
19/09/202417:01GlobeNewswire Inc.Altamira Therapeutics Announces Closing of up to $12.0 Million Public OfferingNASDAQ:CYTOAltamira Therapeutics Ltd
18/09/202417:19Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:CYTOAltamira Therapeutics Ltd
18/09/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYTOAltamira Therapeutics Ltd
17/09/202418:00GlobeNewswire Inc.Altamira Therapeutics Announces Pricing of up to $12.0 Million Public OfferingNASDAQ:CYTOAltamira Therapeutics Ltd
16/09/202414:55Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:CYTOAltamira Therapeutics Ltd
16/09/202409:30GlobeNewswire Inc.Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East AsiaNASDAQ:CYTOAltamira Therapeutics Ltd
03/09/202410:01GlobeNewswire Inc.Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11NASDAQ:CYTOAltamira Therapeutics Ltd
23/08/202410:01GlobeNewswire Inc.Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and DenmarkNASDAQ:CYTOAltamira Therapeutics Ltd
22/08/202417:53Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:CYTOAltamira Therapeutics Ltd
16/08/202410:01GlobeNewswire Inc.Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited SubstancesNASDAQ:CYTOAltamira Therapeutics Ltd
12/08/202410:02GlobeNewswire Inc.Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor ModelsNASDAQ:CYTOAltamira Therapeutics Ltd
19/07/202410:01GlobeNewswire Inc.Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore NanoparticlesNASDAQ:CYTOAltamira Therapeutics Ltd
08/07/202418:17Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:CYTOAltamira Therapeutics Ltd
20/06/202410:01GlobeNewswire Inc.Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo ManagementNASDAQ:CYTOAltamira Therapeutics Ltd
28/05/202411:31GlobeNewswire Inc.Altamira Therapeutics Provides Business UpdateNASDAQ:CYTOAltamira Therapeutics Ltd
23/05/202409:47GlobeNewswire Inc.Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy JournalNASDAQ:CYTOAltamira Therapeutics Ltd
01/05/202409:47GlobeNewswire Inc.Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationNASDAQ:CYTOAltamira Therapeutics Ltd
24/04/202409:47GlobeNewswire Inc.Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed JournalNASDAQ:CYTOAltamira Therapeutics Ltd
10/04/202409:00GlobeNewswire Inc.Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial ResultsNASDAQ:CYTOAltamira Therapeutics Ltd
04/04/202409:45GlobeNewswire Inc.Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024NASDAQ:CYTOAltamira Therapeutics Ltd
25/03/202409:47GlobeNewswire Inc.Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesNASDAQ:CYTOAltamira Therapeutics Ltd
07/02/202410:47GlobeNewswire Inc.Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed JournalNASDAQ:CYTOAltamira Therapeutics Ltd
24/01/202410:47GlobeNewswire Inc.Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer TreatmentNASDAQ:CYTOAltamira Therapeutics Ltd
19/01/202418:40Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CYTOAltamira Therapeutics Ltd
 Apresentando as notícias mais relevantes sobre:NASDAQ:CYTO

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
FICT3
Fictor Alimentos ON
BOV
AGXY3
Agrogalaxy Participacoes ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
AZEV4
AZEVEDO PN
BOV
PRIO3
PETRORIO ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios